Introduction
Type-2 diabetes mellitus (T2DM) remains a primary driver of global cardiovascular morbidity. While sodium-glucose cotransporter-2 inhibitors (SGLT2I) and GLP-1 receptor agonists (GLP1a) have independently demonstrated significant cardioprotective benefits, clinical evidence regarding their combined use is limited. Most clinical trials evaluate these drug classes in isolation, leaving a critical evidence gap for clinicians managing high-risk patients already on GLP1a therapy. This study utilizes real-world data and machine learning-based causal inference to investigate whether adding an SGLT2I to a GLP1a regimen provides additive cardiovascular protection.
Methods
This retrospective population-based cohort study utilized the Clinical Data Analysis and Reporting System (CDARS) from the Hong Kong Hospital Authority, covering the period from January 1, 2015, to December 31, 2020. The cohort included 2,526 T2DM patients already receiving GLP1a therapy, categorized into SGLT2I users (n=1,968) and non-users (n=558).
To ensure robust results, the researchers employed a dual-analytical approach:
- Propensity Score Matching (PSM): Patients were matched at a 1:2 ratio based on demographics, comorbidities, and baseline medications to minimize selection bias.
- Machine Learning Causal Inference: Causal Random Forests (CRF) were applied to estimate the Conditional Average Treatment Effect, accounting for complex, non-linear interactions between patient variables.
The primary outcomes were new-onset myocardial infarction (MI), heart failure (HF), atrial fibrillation, and stroke/TIA. All-cause mortality was the secondary outcome.
Results
The study found that adding SGLT2I to GLP1a therapy significantly reduced the risk of major mechanical cardiovascular events. After adjusting for confounders, non-users of SGLT2I faced a nearly three-fold higher risk of myocardial infarction and a 2.5-fold higher risk of heart failure compared to combination users.
Key findings include:
- Myocardial Infarction: Non-users had a Hazard Ratio (HR) of 2.91 (95% CI: 1.30–6.59).
- Heart Failure: Non-users had an HR of 2.49 (95% CI: 1.22–5.08).
- Clinical Impact: The Number Needed to Treat (NNT) was 49 to prevent one heart attack and 45 to prevent one case of heart failure.
- Other Outcomes: While risks for atrial fibrillation (HR 1.52) and stroke (HR 1.72) were numerically higher in non-users, these did not reach statistical significance.
Subgroup analyses indicated that the benefits of SGLT2I were consistent across various demographics and comorbidities, including age, sex, and the presence of hypertension or hyperlipidaemia.
Discussion and Conclusion
These findings suggest a synergistic cardioprotective effect when SGLT2Is are added to GLP1a therapy. The protection appears most pronounced for "mechanical" cardiac issues (MI and HF) rather than "electrical" (atrial fibrillation) or "vascular" (stroke) issues in this population. Notably, the benefits remained consistent regardless of fasting glucose levels, suggesting that the mechanisms of protection extend beyond simple glycemic control.
While this observational study is limited by the lack of lifestyle data (e.g., BMI, smoking) and the potential for residual confounding, the alignment between traditional statistical models and machine learning causal inference provides strong evidence for the benefits of combination therapy. Future large-scale randomized controlled trials are warranted to confirm these real-world findings.
Summary updated